Why Drugmaker Eli Lilly Is Partnering With ChatGPT Maker OpenAI

Core Insights - Eli Lilly is collaborating with OpenAI to leverage artificial intelligence in developing new treatments for drug-resistant diseases, which are identified as a major public health threat [1][2] - The partnership aims to create novel antimicrobials to combat antimicrobial resistance (AMR), emphasizing the urgency of addressing this global health challenge [1][2] - Eli Lilly has previously committed $100 million to develop two to four new antibiotics by 2030, indicating a strong focus on antibiotic innovation [2] Group 1 - The collaboration with OpenAI is described as a groundbreaking step in addressing antimicrobial resistance, highlighting the potential of generative AI in drug discovery [2] - Eli Lilly's Chief Information and Digital Officer stated that this partnership reflects the company's commitment to tackling significant health challenges globally [2] - The announcement did not disclose any financial terms related to the partnership [2] Group 2 - OpenAI's COO expressed confidence in the potential of AI to drive innovative breakthroughs in the pharmaceutical sector [3] - The pharmaceutical industry has a history of utilizing various forms of AI for drug development, including enhancing manufacturing efficiency and conducting clinical trials [3] - Following the announcement, Eli Lilly's shares increased by 1.6%, and the stock has risen over 55% year-to-date [3]